Cancer of the breast and beta 2 microglobulin

Area of Science:

• Oncology
• Biochemistry
• Clinical Diagnostics

Background:

• Accurate staging of breast carcinoma is crucial for determining patient therapy and prognosis.
• The search for a reliable biochemical marker for disseminated breast cancer is ongoing.
• Serum beta 2 microglobulin (B2M) has been previously investigated as a potential discriminant between localized and systemic disease.

Purpose of the Study:

• To prospectively evaluate the relationship between serum beta 2 microglobulin levels and breast cancer stage.
• To assess the predictive value of B2M for early metastasis in breast cancer patients.
• To determine the usefulness of serial B2M measurements in monitoring treatment response in metastatic breast cancer.

Main Methods:

• A prospective study involving 53 breast cancer patients was conducted over a 2-year period.
• Serum beta 2 microglobulin levels were estimated using a novel assay method.
• Patients were studied repetitively, with B2M levels correlated against disease stage and treatment response.

Main Results:

• No significant correlation was found between serum beta 2 microglobulin levels and the stage of breast cancer at diagnosis.
• Elevated B2M levels did not reliably predict the development of early metastasis.
• While responsive metastatic breast cancer patients generally showed a decrease in B2M, and non-responsive patients showed no change, these alterations were often within the normal range, offering only marginal assessment improvement.

Conclusions:

• Serum beta 2 microglobulin is not a suitable biochemical marker for determining breast cancer stage or predicting metastasis.
• Serial B2M estimations provide limited clinical utility in monitoring treatment response for metastatic breast cancer.
• Further research is needed to identify reliable biochemical markers for breast cancer management.